Laboratory Corporation of America Holdings (LH)

Argus has raised its price target for Labcorp Holdings (LH) to $370 from $310, while maintaining a Buy rating on the stock. This adjustment reflects Argus's continued positive outlook on the company's prospects. The article also briefly mentions recent activities by Labcorp, including the launch of its next-generation Global Trial Connect platform and a new Defense Health Agency contract.

The article highlights the significant lack of up-to-date, verifiable financial data for Labcorp (LH) as of August 31, 2026, making it impossible to accurately assess its recent stock performance or fundamental valuation. While broader market sentiment is positive, specific metrics for Labcorp are unavailable, forcing investors to rely on assumptions rather than concrete figures. The piece then provides a general overview of Labcorp's business in diagnostic testing and its competitive landscape, emphasizing the company's operational model and strategic drivers.

Labcorp (NYSE: LH) has launched an enhanced digital version of its Global Trial Connect™ platform, aiming to improve visibility and simplify workflows for clinical studies. The update, guided by feedback from over 80 sponsors and 100 investigator sites, includes new features like embedded in-portal kit ordering that reduces manual data entry by 75%, a unified Study Oversight Dashboard, and end-to-end sample lifecycle tracking. These enhancements are part of Labcorp's ongoing investment in digital solutions to support more efficient and high-quality clinical trial delivery.

Labcorp announced that members of its executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15th at 11:30 a.m. ET. A live audio webcast will be available on the Labcorp Investor Relations website and archived for 180 days. Labcorp provides innovative laboratory services globally, supporting healthcare decisions and drug development.

Labcorp Holdings (LH) has launched the Elecsys pTau-217 blood test, the first FDA-cleared single biomarker test for Alzheimer's disease, significantly expanding access through primary and specialty care. This new diagnostic tool, along with an alliance with the National Association of Community Health Centers, underscores Labcorp's strategy to integrate new diagnostic tools into routine practice and drive growth through health system partnerships. The company aims for increased ordering volumes for this test to support its margin expansion and earnings growth.